米非司酮治疗子宫内膜异位症的临床疗效及其安全性观察

摘要

Objective:To observe and analyze the clinical effect and safety of mifepristone in the treatment of patients with endometriosis.Method:82 patients with endometriosis were selected as the research object from February 2013 to January 2015,and they were randomly divided into control group(gestrinone treatment group,n=41)and observation group(mifepristone treatment group, n=41),then the total treatment effective rates of different r-AFS stages,incidence of adverse reaction and serum VEGF and its receptors indexes before and after the treatment of two groups were compared.Result:The total treatment effective rates of the observation group with different r-AFS stages were all higher than those of the control group,the incidence of adverse reaction was lower than that of the control group,the serum VEGF and its receptors after the treatment were all lower than those of the control group,the differences were all significant(P<0.05).Conclusion:The clinical effect of mifepristone in the treatment of patients with endometriosis is better,the safety is higher,and it has better control role for the related blood indexes of disease.%目的:观察及分析米非司酮治疗子宫内膜异位症的临床疗效及安全性.方法:选取2013年2月-2015年1月于本院进行治疗的82例子宫内膜异位症患者为研究对象,将其随机分为对照组(孕三烯酮治疗组)41例和观察组(米非司酮治疗组)41例,然后将两组中不同r-AFS分期患者的治疗总有效率、不良反应发生率及治疗前后的血清VEGF及其受体指标进行比较.结果:观察组中不同r-AFS分期患者的治疗总有效率均高于对照组,不良反应发生率低于对照组,治疗后的血清VEGF及其受体指标均低于对照组,比较差异均有统计学意义(P<0.05).结论:米非司酮治疗子宫内膜异位症的临床疗效较好,安全性较高,对于疾病发生中的相关血液指标具有更好的控制作用.